EPITHELIAL OVARIAN CANCER
|
|
- Arline Bates
- 8 years ago
- Views:
Transcription
1 EPITHELIAL OVARIAN CANCER Executive Summary Epithelial ovarian cancer is the most common type of ovarian cancer and the most aggressive gynecological malignancy. Approximately 70% of patients are diagnosed at an advanced stage due to the asymptomatic nature of the disease. Early diagnosis is further hindered by the absence of effective screening tests. First-line screening and diagnosis involves gynecologic examination combined with ultrasonography and CA-125 serum level assessment, but the gold standard for conclusive diagnosis and staging remains surgical excision and further histological examination of the excised adnexal mass. Surgery also provides tumor debulking with ultimate goal to perform complete macroscopic tumor resection (optimal cytoreduction) [1]. Initial response to standard primary treatment including surgical cytoreduction and adjuvant platinum-based combined chemotherapy is approximately 80%. A 5-year survival rate is approximately 40% [2]. Public Health Relevance Epithelial ovarian cancer is not rated as one of the most common human malignancies, but it is a major public health concern due to its disproportionate impact on cancer morbidity and mortality: 238,719 new cases were detected in 2012 [3], an increase in morbidity compared to 225,500 new cases in 2008 [4]. The lifetime risk of epithelial ovarian cancer is approximately 0.7% in sporadic cases and it greatly increases in patients with a familial predisposition (up to 10-40%). The median age at diagnosis for sporadic cancer is 60 years, while predisposed patients may be affected earlier, often in their fifth decade. The age-specific incidence of sporadic disease achieves its peak in people of 75 years and older. Although there has been a statistically significant improvement in treatment results over the last years, ovarian cancer remains the leading cause of gynecologic cancer mortality 151,905 ovarian cancer-related deaths were registered in Nulliparous women and those who have not breastfed are at increased risk for developing ovarian cancer while tubal ligation, oral contraceptives and belonging to African race decreases the risk. Endometriosis is associated with a significantly increased risk of clear-cell, low-grade serous and endometrioid invasive ovarian cancer [5]. The incidence of the disease in developing counties is lower than in developed ones: the incidence of ovarian cancer in South and North America in 2012 was 5.8 and 8.1 per 100,000, respectively. Unfortunately the mortality in developing countries is much higher, probably due to high prevalence of advanced-stage cases and lower level of cancer care. 1
2 Requirements for diagnosis, treatment, and monitoring Diagnostics: At present surgery remains the gold standard for confirming diagnosis and staging ovarian cancer. Laparotomy serves three main purposes in the management of patients with suspected ovarian cancer: 1) to confirm histological type of disease, 2) to determine the extent of disease (staging), which is critical in determining whether postoperative treatment will be necessary, as well as to assess prognosis, 3) to permit debulking of tumor since patients who are optimally cytoreduced (defined as having less than or equal to 1-cm diameter residual tumor) have a better prognosis compared to those with greater amounts of residual disease[6]. Histologic confirmation of the disease should be made on the basis of biopsies of all suspicious sites relevant for staging, such as omentum, mesentery, liver, diaphragm, pelvic and paraaortic lymph nodes [7,8]. Surgery: As noted above surgery is important in diagnosis, staging, and de-bulking. De-bulking surgery is often done at diagnosis, but can also be performed after 3 or 6 cycles of cyto-reductive chemotherapy. Testing: The goal of clinical (preoperative) staging is the confirmation of a malignant adnexal mass, exclusion of another primary tumor, assessment of tumor spread and estimation of possible complications of the disease or further treatment. Computed tomography (CT-scan) or magnetic resonance imaging (MRI) are standard imaging methods for tumor evaluation and post-operative surveillance. If CT-scan and MRI cannot be used (unavailable in developing countries or a patient has contraindications to contrast agents and ionizing radiation exposure) ultrasonography becomes the method of choice. The CA-125 serum level should be assessed. CEA assessment is optional (useful to distinguish serous and mucinous ovarian cancer or metastatic spread to ovary of the colon cancer), α- fetoprotein and β-chorionic gonadotropin help to exclude germ cell tumors in women younger than 40 years old. Some other tests should also be done: blood chemistry for the assessment of renal and hepatic functions (liver enzymes, total bilirubin, albumin and creatinine levels), complete blood count. Administration and Care of Patients: Anticancer drugs for the treatment of ovarian cancer require peripheral or central venous access. Administration can be performed either in outpatient or in-patient facilities. Antiemetic prophylaxis ideally includes administration of 5HT3-antagonists before the start of chemotherapy. Administration of paclitaxel requires the use of dexamethasone, an H2 blocker, and diphenhydramine to prevent hypersensitivity reaction. 2
3 Intravenous vs. Intra-peritoneal Chemotherapy Chemotherapy is most often administered intravenously, but in some studies, some of the agents are administered intra-peritoneally. In some studies this has been associated with a small improvement in survival outcomes, but is technically very difficult to administer, even in resource-rich settings, and we would not recommend this for routine use in most settings. Safety monitoring during chemotherapy requires weekly evaluation of complete blood counts. Patients should regularly visit a medical/general oncologist. Efficacy assessment and follow-up after completion of the treatment should be performed using the same methods of tumor size and spread evaluation which had been used initially. Overview of Regimens Ovarian cancer is a chemo-sensitive disease; therefore chemotherapy is one of the most important components of the systemic treatment. The following tables include information about administration and dosing of different regimens. The standard first-line chemotherapy consists of combination of paclitaxel and carboplatin, both administered intravenously every 3 weeks. Patients with early stage IA-IB with low-grade, or well differentiated adenocarcinoma after adequate staging require observation only. In the case of intermediate prognosis, (stage IA-IB and moderately-well differentiated adenocarcinoma after optimal cytoreduction) 4 cycles of paclitaxel and carboplatin every 3 weeks are prescribed. Chemotherapy for advanced ovarian cancer (stage IC-IV) includes 6 cycles of platinum-based regimens, usually paclitaxel and carboplatin or paclitaxel and cisplatin. The combination of paclitaxel and carboplatin is equally effective but is less toxic and less complex to administer.[14] If taxanes are not available then carboplatin or cisplatin can be given as a single agent, but this is not considered optimal therapy. Bevacizumab is not recommended as part of the standard regimens since it has not shown an increase in overall survival. Standard Regimens for First Line Therapy Paclitaxel + Carboplatin or Cisplatin Carboplatin Intravenous infusion AUC6 Day 1 Paclitaxel Intravenous infusion 175 mg/m 2 Day 1 Cisplatin Intravenous infusion 75 mg/m 2 Day 1 Paclitaxel Intravenous infusion 175 mg/m 2 Day 1 3
4 Second line therapy for patients with recurrent disease after initial chemotherapy Approximately 80% of patients diagnosed with ovarian epithelial cancer will relapse after firstline platinum-based and taxane-based chemotherapy and may benefit from subsequent therapies [9]. Systemic treatment options for patients with recurrent disease are subdivided in three categories according to the platinum-free interval: platinum-refractory progressing during therapy, platinum-resistant recurrence progressing within 6 months after completion of the platinum-based chemotherapy, platinum sensitive progressing after more than 6 months after completion of the platinum-based chemotherapy. Therapeutic options for second line therapy include combinations of platinum compound plus either paclitaxel, gemcitabine, etoposide or doxorubicin as listed in the tables below. All of them have similar efficacy and the choice will be dependent on patient status and drug availability. Usually 6 cycles of chemo within a 3 week interval is recommended. Standard Regimens for Platinum-sensitive relapse ( 6 months): Carboplatin Intravenous infusion AUC5 Day 1 Paclitaxel Intravenous infusion 175 mg/m 2 Day 1 Cisplatin Intravenous infusion 75 mg/m 2 Day 1 Paclitaxel Intravenous infusion 175 mg/m 2 Day 1 Carboplatin Intravenous infusion AUC4 Day 1 Gemcitabine Intravenous infusion 1000 mg/m 2 Days 1,8 Cisplatin Intravenous infusion 75 mg/m 2 Day 1 Etoposide Per os 100 mg 1-7 days Carboplatin Intravenous infusion AUC5 Day 1 Doxorubicin Intravenous infusion 50 mg/m 2 Day 1 Platinum refractory and resistant relapse In case of platinum resistant relapse treatment is focused on quality of life and control of symptoms. Monotherapy of different non-platinum agents has similar efficacy. Various agents, such as doxorubicin, liposomal doxorubicin, etoposide, gemcitabine, topotecan and bevacizumab-containing regimens can be utilized in this situation but extension of life is minimal, and these agents are not recommended to be added to the EML for this indication. Other combinations of anticancer drugs (see Table 3) can be used in treating epithelial ovarian cancer. However, some regimens, such as that including bevacizumab, have only shown progression-free survival without evidence supporting overall survival benefit. Thus, the recommendations only consider the standard regimens listed above. 4
5 Review of Benefits and Harms Benefits First line chemotherapy (paclitaxel/platinum) with our without surgery, results in a high remission rate, though as noted below, a high relapse rate. Nonetheless, patients treated with first line therapy have a significant prolongation in survival, and 20% or more are long-term survivors. Therefore the benefit of first-line chemotherapy is significant. Administration of platinum-based regimens in first-line chemotherapy is highly important and improves progression-free survival up to 18 months and overall survival to 44 months [10]. Median overall survival has improved from months two decades ago to months and at present the 5-year overall survival is about 44% [10]. There is no benefit from adding a third chemotherapy agent to standard chemotherapy [11]. The risk of recurrence in ovarian cancer after first line therapy is approximately 80% [9]. The probability of response to second-line chemotherapy depends on the progression-free interval after the last dose of the preceding line of chemotherapy. Patients with platinum-resistant ovarian cancer comprise a poor prognosis population, characterized by low response rates (<10%) with short expected overall survival [12]. Administration of doublets does not improve progression-free survival but increases toxicity in contrast with monotherapy with non-platinum agents. For platinum-sensitive ovarian cancer carboplatin doublets is the treatment of choice. The results of the trials, which compared different platinum-based regimens, were controversial in terms of PFS improvement. Nevertheless the overall survival benefit was observed in patients receiving carboplatin and paclitaxel only [13]. Harms and Toxicity Considerations Common Patients receiving treatment for ovarian cancer experience common drug toxicity reactions. Most patients suffer hematological toxicity from the medication combination including neutropenia, thrombocytopenia, and anemia, all of which are typically rapidly reversible upon discontinuation of agents.[11,13] Paclitaxel can cause hypersensitivity reactions in up to 30% of patients and requires premedication to reduce the risk of these reactions. Paclitaxel frequently causes alopecia and peripheral neuropathy, which is often mild and reversible. [13,15] Cisplatin and carboplatin can cause severe, potentially dose-limiting nausea and vomiting requiring pretreatment with anti-emetics. Serious In approximately 10-30% of cases, cisplatin causes nephrotoxicity which may result in electrolyte abnormalities, aggressive IV hydration is necessary to reduce this risk. [13] Doxorubicin is associated with the risk of congestive heart failure, however the risk is small (<1%) in patients receiving < mg/m 2 cumulative dose, as in the regimens above.[16] 5
6 Systematic Reviews The following systematic reviews and meta-analyses summarize the literature supporting the use of named regimens: Coleman RL et al. Latest research and clinical treatment of advanced-stage epithelial ovarian cancer Nat Rev Clin Oncol April ; 10(4): o Available data on second line therapy for recurrent disease is summarized in the tables below from Coleman et al. Stronger data is available for platinum-sensitive disease, where recurrence is documented more than 6 months after platinum-based therapy versus platinum-resistant disease, where recurrence is documented within 6 months of platinum-based therapy. Patients with platinum-sensitive disease have significantly better PFS and OS. F. A. Raja et al. Optimal first-line treatment in ovarian cancer Ann Oncol (2012) 23 (suppl 10): x118-x127. o For women with stage Ic and above, clear cell histology, or other high-risk features, adjuvant chemotherapy with carboplatin and paclitaxel is recommended based on ICON 1 and EORTC ACTION trials. Analyzed together, they enrolled >900 patients and showed improvement in RFS (76% vs 65% P = 0.001) and OS (82% ves74% P = 0.008) at 5 years, maintained in 10 year follow-up. Greatest effect of chemotherapy in patients with sub-optimal surgery. No RCT evidence of benefit of adding paclitaxel as compared with carboplatin alone, but it is generally given if available. Mounting evidence that chemotherapy can be given neoadjuvantly with equivalent or improved result compared to adjuvantly. While six cycles of carboplatin are common given, three cycles were shown to be equivalent in GOG 157: RFS at three year follow-up for 6 cycles was 24% lower (HR: 0.761; 95% CI: , p=0.18), nearly identical observed death rates (HR: 1.02; 95% CI: ). 6
7 Two Tables from Coleman et al 2013 REVIEWS EVIEWS Table 3 Most-frequently used agents in platinum-resistant disease Agent Response rate (%) PFS (months) Overall survival (months) Side effects Pegylated liposomal Hand foot syndrome; doxorubicin 71,72 mucositis Comments Most frequently prescribed as every 4 weeks schedule Topotecan 71, Myelosuppression Daily for 5 days or weekly administration used Docetaxel Myelosuppression Single GOG trial with very good results Gemcitabine 72, Myelosuppression Also data with platinums in resistant disease; 127 approved for platinumsensitive disease with carboplatin Pemetrexed Myelosuppression Not approved in ovarian cancer Etoposide 129, Myelosuppression Activity, dose and population dependent Paclitaxel Myelosuppression; neuropathy Nab-paclitaxel Myelosuppression; neuropathy Bevacizumab Hypertension; proteinuria; thrombosis Chemotherapy* 13 vs ± bevacizumab 68 vs 6.7 Pending Adding bevacizumab increased hypertension; proteinuria Usually administered weekly in this setting Not approved in ovarian cancer Not approved in ovarian cancer in the USA; pivotal phase II supporting phase III front-line and recurrence investigation Overall survival pending; bevacizumab not approved in ovarian cancer *Allowable chemotherapy regimens in this study were paclitaxel (weekly), pegylated liposomal doxorubicin; topotecan (two infusion styles: weekly, daily for 5 days). Abbreviations: GOG, Gynecologic Oncology Group; PFS, progression-free survival. common grade 3 or 4 event (16 17% both cohorts) with Furthermore, if the time from previous platinum and peripheral Table 4 Pivotal neuropathy clinical trials (5%) in and the hand foot platinum-sensitive syndrome recurrent taxane settingtreatment has been short, then often a regimen (4.5%) Study being more Agents common in the experimental cohort RR compared to the control. Overall survival has not been (%) is PFS selected that PFS incorporates HRs Overall an survival alternative Overall to taxane, such (months) as gemcitabine or PLD. (months) Besides altering survival the HRs toxicity reported, ICON 4 but publication Carboplatin* is anticipated profile, a 0.76 different mechanism 24 of action 0.82 is invoked by (n = 802) 132 Carboplatin + paclitaxel 66 changing 12 the P second <0.001 agent 29 paired with platinum. P = 0.02 More Platinum-sensitive AGO Carboplatin disease 31 recently, 5.8 with 0.72 the discovery 17.3 of other active 0.96cytotoxic Platinum-sensitive (n = 366) 133 Gemcitabine disease + carboplatin is defined as patients whose 47 recurrence CALYPSO is documented Carboplatin + paclitaxel greater than 6 months after platinum-based (n = 976) 134 Carboplatin therapy. 64,68 + PLD These patients have a much better OCEANS prognosis Gemcitabine than the + categories carboplatin + above placeboin terms 57 of agents, 8.6 non-platinum P = combinations 18 are becoming P = 0.73 more common Contemporary trials in platinum-sensitive 0.99 disease 11.3 have P incorporated = targeted biological P = 0.87 agents, as outlined 8.4 below 0.48 in the novel 35.2agent focus section longevity, (n = 484) 135 as many Gemcitabine will respond + carboplatin to multiple + bevacizumab regimens P < P = 0.84 Generally these patients are treated with a platinumbased Recurrent disease therapy Immature data *Other combination. non-taxane combinations Platinum-sensitive were allowed. Abbreviations: disease HR, hazard is a broad ratio; PFS, progression-free Most patients survival; diagnosed PLD, pegylated with liposomal recurrent doxorubicin; disease RR, response will have rate. category that can be rather heterogeneous, because those who recur just over 6 months after receiving platinumbased a multifocal distribution of implants that mimic their presentation at initial diagnosis. In this respect, it is not among therapy carefully can selected behave patients. more like One platinum-resistant clear factor difficult between to institutions. understand clinicians Endoscopic and evaluation, patients interest similar in patients the consideration than those for who surgical recur intervention later; response in medically rates and secondary to that used surgical by clinicians cytoreduction. identify Unfortunately, appropri despite candidates significant for primary attention cytoreduction, this topic has has received also been from used. clini- time-to-event fit patients is their data underlying improve incrementally potential to as respond the time to the interval adjuvant from therapy. prior Although chemotherapy this is an imperfect until recurrence science, increases. the probability Thus, some of responding authors have to advocated secondary that chemotherapy recur seems earlier, to be specifically a positively between sloped 6 12 linear months, relation- be those who labelled ship with as treatment partially or and intermediately platinum-free sensitive. interval In These this patients regard, patients can be treated with long in a treatment similar way or platinum-free to sensitive intervals (>24 patients months who from recur first-line after 12 treatment months; however, completion) have anticipated advocated outcomes, for the consideration such as response of single- rate, some agent PFS and therapies overall survival used in similar platinum-resistant to those with treatmentnaive disease. 81 The impact combinations. of even 78 a subtotal resection disease or non-platinum-based may A have number merit of in platinum-based this situation. 82,83 combinations However, given that can be the used median in patients PFS from with most platinum-sensitive phase III front-line disease trials (Table ranges between 4). Often, 10 patients and 24 months, are treated the majority with platinumbasedates with and taxane-based recurrent disease chemotherapy will fall into again; a category however, of of candical Benedetti-Panici investigation, guidance and colleagues as to its role reported in the setting that no of recurrent visible residual disease disease not was clear. achieved 18 In addition, in 79% interpretation prescreened of the available by imaging data is and difficult exam at who the minimum, subsequently and of patients hazard underwent ous at pre the resection extreme, endoscopy. because of the As inherent other selection patient bias selection that exists was in tightly reviews controlled of clinical with experience 60% of the at trials, one operative or more sample institutions. presenting Even with reports solitary that are recurrence based on observations masses. The AGO of prospectively identified a collected panel of features patients in cannot their be initial reliably retrospective compared study to historical on the observations topic (DESKTOP owing I to trial), inability and to validated control for their variations predictive in practice model in patterns, a subsequent selection study. 88 and They assessment found that models. patients This who situation had a patient has performance placed a premium status of 0 on or phase 1, with III early investigation, stage disease, which or fortunately had no visible underway. tumour residuum following initial surgical Despite cyto reduction the uncertainty, and no most ascites practitioners were likely strongly (>67%) 7
8 Recommendations The reviewers recommend the incorporation of epithelial ovarian cancer treatment options into the WHO Model List of Essential Medicines, and recommend specifically that cisplatin and gemcitabine be added to the core Essential Medicines List. Additions proposed for Section 8.2 of the EML Cisplatin* Gemcitabine *Carboplatin is currently in the WHO Essential Medicines List for Adults (2013, 18 th Edition). Next to Carboplatin in the list is a symbol that indicates that the listing of the drug indicates similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources. Not all square boxes are applicable to medicine selection for children see the second EMLc for details. Therapeutic equivalence is only indicated on the basis of reviews of efficacy and safety and when consistent with WHO clinical guidelines. National lists should not use a similar symbol and should be specific in their final selection, which would depend on local availability and price. The present proposal calls for the explicit addition of Cisplatin to the EML given its distinct use in the treatment of a number of cancers. 8
9 References EPITHELIAL OVARIAN CANCER 1. Stuart GC, Kitchener H, Bacon M, et al Gynecologic Cancer Intergroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011;21: Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer J Clin 2013;63: Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; Available from: accessed on 23/Sep/ Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin Mar-Apr;61(2): Pearce CL, Templeman C, Rossing MA et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol Apr;13(4): Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20: Olson SH, Mignone L, Nakraseive C, et al. Symptoms of ovarian cancer. Obstet Gynecol 2001;98: Goff BA, Mandel L, Muntz HG, et al. Ovarian carcinoma diagnosis. Cancer 2000;89: Lederman JA., Raja FA., Fotopoulou C. et al. Newly diagnosed and relapsed epithelial ovarian cancer carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl.6): Raja F.A., Chopra N, Ledermann J.A. et al. Optimal first-line treatment in ovarian cancer. Ann. Oncol. 2012; 23 (suppl 10): Bookman MA, Brady MF, McGuire WP. et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27: Coleman RL Monk BJ, Sood AK, Herzog TJ. Latest research and clinical treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol April; 10(4): Parmar MK, Lederman JA, Colombo N. et al. Paclitaxel and platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 tial. Lancet 2003; 361: Ozols RF, Bundy BN, Greer E, et al. Phase III trials of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecology Oncology Group Study. J Clin Oncol 2003; 21: Castells MC, Matulonis UA. Infusion reactions to systemic chemotherapy. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA, Floyd J, Morgan JP. Cardiotoxicity of anthracycline-like chemotherapy agents. Post TW (Ed), UpToDate, Waltham, MA,
Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More informationManagement of Platinum-Sensitive Recurrent Ovarian Cancer
Management of Platinum-Sensitive Jacobus Pfisterer a and Jonathan A. Ledermann b The majority of patients with ovarian cancer will relapse despite state-of-the-art first-line surgery and chemotherapy.
More informationSelecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer. Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK
Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK Overview of Presentation This presentation will discuss the management
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationOvarian cancer. A guide for journalists on ovarian cancer and its treatment
Ovarian cancer A guide for journalists on ovarian cancer and its treatment Contents Contents 2 3 Section 1: Ovarian Cancer 4 i. Types of ovarian cancer 4 ii. Causes and risk factors 5 iii. Symptoms and
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationCycle frequency: Every three weeks Total number of cycles: 6
Carboplatin/Paclitaxel Ovarian Cancer Adjuvant, Advanced Paclitaxel 175mg/m 2 500mls 5% dex/3hrs Day 1 Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Anti-emetic group - Moderately high Paclitaxel given first
More informationwith ovarian cancer exhibit an initial response. 5 In addition, the majority of
Research ONCOLOGY Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer Laura J. Havrilesky, MD, MHSc; Thomas C. Krivak, MD; John W. Mucenski, PharmD; Evan R. Myers, MD, MPH OBJECTIVE:
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationLatest developments in management. Gianfilippo Bertelli Consultant Medical Oncologist Swansea
Latest developments in management Gianfilippo Bertelli Consultant Medical Oncologist Swansea Optimizing management of ovarian cancer in South Wales Diagnosis and referral pathways: Role of GPs, gynaecologists,
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationChapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationFirst-line chemotherapy for the treatment of women with epithelial ovarian cancer
First-line chemotherapy for the treatment of women with epithelial ovarian cancer Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer June 2014
More informationFrequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationMaintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence
Journal of BUON 17: 735-739, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Maintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationFirst-line chemotherapy for women with epithelial ovarian cancer
First-line chemotherapy for women with epithelial ovarian cancer A systematic review July 2013 First line chemotherapy for women with epithelial ovarian cancer: a systematic review was prepared and produced
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationSchedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8
Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total
More informationCOMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER
COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationCarcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
More informationCHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationSystematic evaluation of bevacizumab in recurrent ovarian cancer treatment
JBUON 2014; 19(4): 965-972 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationUnderstanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org
Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS foundationforwomenscancer.org Contents Introduction...1 CA 125................................... 1 The CA 125 Test...2 The Use of the CA
More informationThe role of PARP inhibitors in high grade serous ovarian cancers
The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair
More informationOvarian Cancer (Event Driven)
Brochure More information from http://www.researchandmarkets.com/reports/2367241/ Ovarian Cancer (Event Driven) Description: Owing to the lack of screening programs across the markets under study, ovarian
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationSummary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationBCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)
BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) Protocol Code Tumour Group Contact Physician UGUTIP Genitourinary Dr.
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationOvarian Cancer Treatment 2014 and beyond
Ovarian Cancer Treatment 2014 and beyond RK Potkul, MD, FACS, FACOG Mary Isabelle Caestecker Professor and Chair Department of Obstetrics and Gynecology Stritch School of Medicine Loyola University Chicago
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationSafe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer
Safe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer Camran Nezhat,, MD, FACOG, FACS Stanford University Medical Center Center for Special Minimally Invasive
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationChing-Yao Yang, Yu-Wen Tien
Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
More informationLung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)
Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationCytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
More informationTreatment options for recurrent ovarian cancer
Treatment options for recurrent ovarian cancer There are a number of treatment options for women with recurrent ovarian cancer. Chemotherapy is the treatment most commonly offered and on occasion, surgery
More informationRecommendation Strength Strong, supported by the evidence and expert consensus. Recommendation Benefit/Harm Evidence Quality
CHEMO- AND TARGETED THERAPY FOR WOMEN WITH HER2 NEGATIVE (OR UNKNOWN) ADVANCED BREAST Benefit/Harm Evidence Quality 1: Endocrine therapy, rather than chemotherapy, should be offered as the standard firstline
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationTricia Cox on 7/18/2012 at Oncology Center. Sarah Randolf. Female
SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,
More informationPRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology
PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI
More informationCycle frequency: Every three weeks Total number of cycles: 3 or 4
BEP 3-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Bleomycin 30,000iu 200mls N. Saline/30mins Days 2, 8 & 15 Etoposide 165mg/m 2 1L N. Saline/1hr Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/4hrs
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012
Background LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012 The incidence of pancreatic cancer in the UK is 9.4/100,000. It is
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationMedication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More informationPOLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
More informationSchedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2
Doxorubicin/Cisplatin Osteosarcoma - neoadjuvant Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 (3 before surgery) Ensure adequate renal function Pre & post-hydration,
More informationHematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer
Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Policy Number: Original Effective Date: MM.07.014 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 01/23/2015 Section:
More informationOut-Patient Chemotherapy for Lung Cancer
Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationHow valuable is a cancer therapy? It depends on who you ask.
How valuable is a cancer therapy? It depends on who you ask. Comparing and contrasting the ESMO Magnitude of Clinical Benefit Scale with the ASCO Value Framework in Cancer Ram Subramanian Kevin Schorr
More informationMesothelioma. Information for Patients and Families. identifying and evaluating experimental
Mesothelioma CLINICAL TRIALS Information for Patients and Families identifying and evaluating experimental treatments table of contents Pg. 2... Phases of a Clinical Trial Pg. 3... Mesothelioma and Clinical
More informationThe Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationWest of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)
West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationNetwork Chemotherapy Regimens
Network Chemotherapy Regimens Lung Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.org.uk. Any correspondence about the protocols
More informationIntraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (Review)
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (Review) Jaaback K, Johnson N, Lawrie TA This is a reprint of a Cochrane review, prepared and maintained by
More informationBNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
More informationA Review of Cost-Effectiveness Studies in Ovarian Cancer
Several studies on cost-effectiveness in ovarian cancer management have been reported that inform optimal therapy. J. L. Munro. Sheep Farm in Winter. Mixed media on canvas, 24 48. A Review of Cost-Effectiveness
More informationTargeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany
Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee
More informationSurgical Staging of Endometrial Cancer
Surgical Staging of Endometrial Cancer I. Endometrial Cancer Surgical Staging Overview Uterine cancer types: carcinomas type I and type II, sarcomas, carcinosarcomas Hysterectomy with BSO Surgical Staging
More informationWhat is the reference cytotoxic regimen in advanced gastric cancer?
What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.
More informationSentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
More informationCycle frequency: Every four weeks Total number of cycles: 6-8
Fludarabine Low Grade non-hodgkin s Lymphoma and CLL Fludarabine 25mg/m 2 oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6-8 Anti-emetic group Low Prophylactic co-trimoxazole and
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More informationScottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
More informationGynäkologische Onkologie-Klinische Studien
Gynäkologische Onkologie-Klinische Studien Breast cancer A randomized, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer
More information